FiercePharma1d
'We cannot stay silent': Novo Nordisk flags dangers of compounded GLP-1s following Hims & Hers Super Bowl ad
Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...
BioSpace1d
Novo’s Semaglutide Shows Promise for Alcohol Use Disorder
The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...
Business Insider28d
Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial
“Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide ...
pharmaphorum25d
Lilly, Novo Nordisk sued over GLP-1 drug safety
Novo Nordisk already has approval for semaglutide under the Wegovy brand for obesity, while Lilly is in the process of seeking approval to add weight loss to the label of Mounjaro. Both drugs are ...
FiercePharma28d
Novo's semaglutide among 2nd batch of drugs selected for IRA price negotiations
The list of 15 medicines includes blockbuster drugs from Novo Nordisk, Pfizer, Bristol Myers Squibb, AstraZeneca, GSK and other companies. Novo’s booming semaglutide franchise for diabetes and ...
Yahoo Finance28d
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial ...
The Hill28d
CMS to seek Medicare negotiations on Ozempic price
The CMS listed Ozempic, Rybelsus and Wegovy — all forms of semaglutide — at the top ... in the U.S. Danish pharmaceutical giant Novo Nordisk is the manufacturer of Ozemipc; its diabetes ...